Headlines about Mirna Therapeutics (NASDAQ:MIRN) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mirna Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the near future.

Separately, Cantor Fitzgerald reiterated a “hold” rating and set a $2.00 target price on shares of Mirna Therapeutics in a research note on Thursday, April 13th. Six research analysts have rated the stock with a hold rating, Mirna Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.63.

Shares of Mirna Therapeutics (MIRN) traded up 9.20% during trading on Friday, reaching $1.90. The company had a trading volume of 42,571 shares. Mirna Therapeutics has a 12 month low of $1.12 and a 12 month high of $4.45. The firm’s market capitalization is $39.63 million. The stock has a 50 day moving average price of $1.53 and a 200 day moving average price of $1.93.

WARNING: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.watchlistnews.com/mirna-therapeutics-nasdaqmirn-given-media-sentiment-score-of-0-05/1442269.html.

Mirna Therapeutics Company Profile

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

Insider Buying and Selling by Quarter for Mirna Therapeutics (NASDAQ:MIRN)

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.